Why sex and gender matter in cancer research and care

Czech version

Authors: J. Staňková; M. Hajdúch
Authors‘ workplace: Ústav molekulární a translační medicíny LF UK a FN Olomouc
Published in: Klin Onkol 2025; 38(6): 436-446
Category: Reviews
doi: https://doi.org/10.48095/ccko2025436

Overview

Background: Biological sex and gender significantly influence cancer incidence, biology, disease progression, treatment response, and long-term survival. These differences arise from a complex interplay of hormonal, genetic, epigenetic, immunological, and behavioral factors. Notable disparities have been observed in colorectal, lung, and bladder cancers –⁠ including histological subtypes, immune responses, and treatment outcomes. Women are more susceptible to chemotherapy toxicity, often face delayed diagnosis, and experience higher psychosocial burden. In contrast, men tend to show higher cancer-related morbidity and mortality. Transgender and non-binary individuals remain largely underrepresented in cancer research. Furthermore, preclinical models frequently overlook the sex of animal or cellular samples, limiting translational relevance. Emerging technologies –⁠ such as multi-omics approaches, 3D human organoids, and artificial intelligence –⁠ provide promising tools to better understand sex-specific mechanisms in cancer development and treatment, and will enable future personalization of oncological care according to the patient’s sex. Purpose: This review aims to summarize current knowledge on the influence of biological sex and gender on cancer incidence, tumor biology, and therapeutic response, with additional focus on behavioral and psychosocial factors. Special attention is given to colorectal, lung, and bladder cancers as model malignancies with sex-specific differences, and to the ongoing challenges in preclinical research and clinical practice. Conclusion: Sex and gender are key determinants of oncological outcomes and should be systematically incorporated into research design, clinical trial methodology, personalized therapy, and health policy. Their integration is not only a scientific imperative but also an ethical necessity on the path toward precise and equitable cancer care.

Keywords:

precision medicine – neoplasms – research – Gender identity – sex

Sources

1. Tannenbaum C, Ellis RP, Eyssel F et al. Sex and gender analysis improves science and engineering. Nature 2019; 575 (7781): 137–146. doi: 10.1038/s41586-019-1657-6.

2. Haupt S, Carcel C, Norton R. Neglecting sex and gender in research is a public-health risk. Nature 2024; 629 (8012): 527–530. doi: 10.1038/d41586-024-01372-2.

3. Ritz SA, Greaves L. We need more-nuanced approaches to exploring sex and gender in research. Nature 2024; 629 (8010): 34–36. doi: 10.1038/d41586-024-01204-3.

4. Conforti F, Pala L, Di Mitri D et al. Sex hormones, the anticancer immune response, and therapeutic opportunities. Cancer Cell 2025; 43 (3): 343–360. doi: 10.1016/j.ccell.2025.02.013.

5. LeResche L. Defining gender disparities in pain management. Clin Orthop Relat Res 2011; 469 (7): 1871–1877. doi: 10.1007/s11999-010-1759-9.

6. Woitowich NC, Beery A, Woodruff T. A 10-year follow-up study of sex inclusion in the biological sciences. Elife 2020; 9: e56344. doi: 10.7554/eLife.56344.

7. Ramirez FD, Motazedian P, Jung RG et al. Sex bias is increasingly prevalent in preclinical cardiovascular research: implications for translational medicine and health equity for women. Circulation 2017; 135 (6): 625–626. doi: 10.1161/CIRCULATIONAHA.116.026668.

8. Itoh Y, Arnold AP. Are females more variable than males in gene expression? Meta-analysis of microarray datasets. Biol Sex Differ 2015; 6 (1): 18. doi: 10.1186/s13293-015-0036-8.

9. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020; 396 (10250): 565–582. doi: 10.1016/S0140-6736 (20) 31561-0.

10. Research and innovation. Gendered innovations 2: how inclusive analysis contributes to research and innovation. 2020 [online]. Dostupné z: https: //research -⁠ and-innovation.ec.europa.eu/knowledge-publications-tools-and-data/publications/all-publications/gendered-innovation-2-how-inclusive-analysis-contributes-research-and-innovation_en.

11. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature 2014; 505 (7485): 612–613. doi: 10.1038/505612a.

12. Galea LAM, Choleris E, Albert AYK et al. The promises and pitfalls of sex difference research. Front Neuroendocrinol 2020; 56 : 100817. doi: 10.1016/j.yfrne.2019.100817.

13. Heidari S, Babor TF, De Castro P et al. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 2016; 1 (1): 2. doi: 10.1186/s41073-016-0007-6.

14. Yuan Y, Liu L, Chen H et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 2016; 29 (5): 711–722. doi: 10.1016/j.ccell.2016.04.001.

15. Jackson SS, Marks MA, Katki HA et al. Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors. Cancer 2022; 128 (19): 3531–3540. doi: 10.1002/cncr.34390.

16. Clocchiatti A, Cora E, Zhang Y et al. Sexual dimorphism in cancer. Nat Rev Cancer 2016; 16 (5): 330–339. doi: 10.1038/nrc.2016.30.

17. Ben-Batalla I, Vargas-Delgado ME, Meier L et al. Sexual dimorphism in solid and hematological malignancies. Semin Immunopathol 2019; 41 (2): 251–263. doi: 10.1007/s00281-018-0724-7.

18. Massey SC, Whitmire P, Doyle TE et al. Sex differences in health and disease: a review of biological sex differences relevant to cancer with a spotlight on glioma. Cancer Lett 2021; 498 : 178–187. doi: 10.1016/j.canlet.2020. 07.030.

19. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16 (10): 626–638. doi: 10.1038/nri.2016.90.

20. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (3): 229–263. doi: 10.3322/caac.21834.

21. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91 (14): 1194–1210. doi: 10.1093/jnci/91.14.1194.

22. O’Sullivan JF, Martin K, Caplice NM. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis. J Am Coll Cardiol 2011; 57 (4): 383–389. doi: 10.1016/j.jacc.2010.09.029.

23. Thun MJ, Carter BD, Feskanich D et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368 (4): 351–364. doi: 10.1056/NEJMsa1211127.

24. Dieleman LA, van Peet PG, Vos HMM. Gender differences within the barriers to smoking cessation and the preferences for interventions in primary care a qualitative study using focus groups in The Hague, The Netherlands. BMJ Open 2021; 11 (1): e042623. doi: 10.1136/bmjopen-2020-042623.

25. Bottorff JL, Haines-Saah R, Kelly MT et al. Gender, smoking and tobacco reduction and cessation: a scoping review. Int J Equity Health 2014; 13 (1): 114. doi: 10.1186/s12939-014-0114-2.

26. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4 (8): 579–591. doi: 10.1038/nrc1408.

27. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010; 61 (1): 301–316. doi: 10.1146/annurev.med.080708.082713.

28. Kittnar O. Selected sex related differences in pathophysiology of cardiovascular system. Physiol Res 2020; 69 (1): 21–31. doi: 10.33549/physiolres.934068.

29. Wilcox NS, Amit U, Reibel JB et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol 2024; 21 (9): 617–631. doi: 10.1038/s41569-024-01017-x.

30. Olmos VJ, Severo AS, Auňón PZ et al. Cardio-oncology at present: a pending challenge. Rev Esp Cardiol (Engl Ed) 2022; 75 (8): 695–696. doi: 10.1016/j.rec.2022.0 5.010.

31. Zvolská K, Králíková E, Volurka S et al. Treatment of tobacco dependence in cancer patients –⁠ recommendations of the Section of Supportive Treatment and Care and the Section of Preventive Oncology of the Czech Cancer Society of the Czech Medical Association of J. E. Purkyně, Working Group for the Prevention and Treatment of Tobacco Dependence of the Czech Medical Association of J. E. Purkyně, and the Society for Treatment of Tobacco Dependence. Klin Onkol 2024; 37 (1): 63–67. doi: 10.48095/ccko202463.

32. Zheng D, Williams C, Vold JA et al. Regulation of sex hormone receptors in sexual dimorphism of human cancers. Cancer Lett 2018; 438 : 24–31. doi: 10.1016/j.canlet.2018.09.001.

33. Bhat M, Pasini E, Pastrello C et al. Estrogen receptor 1 inhibition of wnt/b-catenin signaling contributes to sex differences in hepatocarcinogenesis. Front Oncol 2021; 11 : 777834. doi: 10.3389/fonc.2021.777834.

34. Samarkina A, Youssef MK, Ostano P et al. Androgen receptor is a determinant of melanoma targeted drug resistance. Nat Commun 2023; 14 (1): 6498. doi: 10.1038/s41467-023-42239-w.

35. Clocchiatti A, Ghosh S, Procopio MG et al. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J Clin Invest 2018; 128 (12): 5531–5548. doi: 10.1172/JCI99159.

36. Cardano M, Buscemi G, Zannini L. Sex disparities in P53 regulation and functions: novel insights for personalized cancer therapies. Cells 2025; 14 (5): 363. doi: 10.3390/cells14050363.

37. Kaneko S, Li X. X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci Adv 2018; 4 (6): eaar5598. doi: 10.1126/sciadv.aar5598.

38. Cáceres A, Jene A, Esko T et al. Extreme downregulation of chromosome Y and cancer risk in men. J Natl Cancer Inst 2020; 112 (9): 913–920. doi: 10.1093/jnci/djz232.

39. Raymond JH, Aktary Z, Pouteaux M et al. Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin. Nature 2025; 643 (8072): 801–809. doi: 10.1038/s41586-025-09111-x.

40. Hermann CD, Schoeps B, Eckfeld C et al. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. J Exp Med 2021; 218 (11): e20210911. doi: 10.1084/jem.20210911.

41. Contractor T, Kobayashi S, da Silva E et al. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016; 7 (21): 30585–30596. doi: 10.18632/oncotarget.8874.

42. Ippolito JE, Yim AKY, Luo J et al. Sexual dimorphism in glioma glycolysis underlies sex differences in survival. JCI Insight 2017; 2 (15): e92142. doi: 10.1172/jci.insight.92142.

43. Davidson M, Wagner AD, Kouvelakis K et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials. Eur J Cancer 2019; 121 : 40–47. doi: 10.1016/j.ejca.2019.08.010.

44. Delahousse J, Wagner AD, Borchmann S et al. Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open 2024; 9 (12): 104002. doi: 10.1016/j.esmoop.2024.104002.

45. Sharifi S, Caracciolo G, Pozzi D et al. The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine. Adv Drug Deliv Rev 2021; 174 : 337–347. doi: 10.1016/j.addr.2021.04.028.

46. Yu Y, Chen J, Li D et al. Systematic analysis of adverse event reports for sex differences in adverse drug events. Sci Rep 2016; 6 (1): 24955. doi: 10.1038/srep24955.

47. Frost MG, Jensen KJ, Jimenez-Solem E et al. Sex disparities in advanced non-small cell lung cancer survival: a Danish nationwide study. Lung Cancer 2025; 202 : 108485. doi: 10.1016/j.lungcan.2025.108485.

48. Koo JH, Leong RW. Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. J Gastroenterol Hepatol 2010; 25 (1): 33–42. doi: 10.1111/j.1440-1746.2009.05992.x.

49. Korenaga D, Orita H, Okuyama T et al. Sex hormone-receptor-negative tumors have a higher proliferative activity than sex hormone-receptor-positive tumors in human adenocarcinomas of the gastrointestinal tract. Surg Today 1998; 28 (10): 1007–1014. doi: 10.1007/ BF02483953.

50. Bellenghi M, Puglisi R, Pontecorvi G et al. Sex and gender disparities in melanoma. Cancers (Basel) 2020; 12 (7): 1819. doi: 10.3390/cancers12071819.

51. Capone I, Marchetti P, Ascierto PA et al. Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy. Front Immunol 2018; 9 : 552. doi: 10.3389/fimmu.2018.00552.

52. Haupt S, Caramia F, Klein SL et al. Sex disparities matter in cancer development and therapy. Nat Rev Cancer 2021; 21 (6): 393–407. doi: 10.1038/s41568-021-00348-y.

53. Gal-Oz ST, Maier B, Yoshida H et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun 2019; 10 (1): 4295. doi: 10.1038/s41467-019-12348-6.

54. Wagner AD, Oertelt-Prigione S, Adjei A et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 2019; 30 (12): 1914–1924. doi: 10.1093/annonc/mdz414.

55. Choi Y, Kim N. Sex difference of colon adenoma pathway and colorectal carcinogenesis. World J Mens Health 2024; 42 (2): 256–282. doi: 10.5534/wjmh.230085.

56. Kaku E, Oda Y, Murakami Y et al. Proportion of flat -⁠ and depressed-type and laterally spreading tumor among advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2011; 9 (6): 503–508. doi: 10.1016/j.cgh.2011.03.018.

57. Martinez A, Hamieh N, Colineaux H et al. Influence of sex on the incidence of colorectal cancer: considering the influence of gender mechanisms. Soc Sci Med 2025; 376 : 118058. doi: 10.1016/j.socscimed.2025.118058.

58. Ngo O, Hejcmanová K, Suchánek Š et al. Coverage by examinations associated with early detection of colorectal neoplasia in the Czech Republic. Eur J Public Health 2023; 33 (3): 515–521. doi: 10.1093/eurpub/ckad071.

59. Abancens M, Bustos V, Harvey H et al. Sexual dimorphism in colon cancer. Front Oncol 2020; 10 : 607909. doi: 10.3389/fonc.2020.607909.

60. Kim SE. Sex -⁠ and gender-specific disparities in colorectal cancer risk. World J Gastroenterol 2015; 21 (17): 5167–5175. doi: 10.3748/wjg.v21.i17.5167.

61. Devall M, Eaton S, Yoshida C et al. Assessment of colorectal cancer risk factors through the application of network-based approaches in a racially diverse cohort of colon organoid stem cells. Cancers (Basel) 2023; 15 (14): 3550. doi: 10.3390/cancers15143550.

62. Gee K, Yendamuri S. Lung cancer in females –⁠ sex -⁠ -based differences from males in epidemiology, biology, and outcomes: a narrative review. Transl Lung Cancer Res 2024; 13 (1): 163–178. doi: 10.21037/tlcr-23-744.

63. Florez N, Kiel L, Riano I et al. Lung cancer in women: the past, present, and future. Clin Lung Cancer 2024; 25 (1): 1–8. doi: 10.1016/j.cllc.2023.10.007.

64. MacRosty CR, Rivera MP. Lung cancer in women. Clin Chest Med 2020; 41 (1): 53–65. doi: 10.1016/j. ccm. 2019.10.005.

65. Rehulkova A, Chudacek J, Prokopova A et al. Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients. Transl Lung Cancer Res 2023; 12 (5): 1034–1050. doi: 10.21037/ tlcr-22-801.

66. Koudelakova V, Kneblova M, Trojanec R et al. Non-small cell lung cancer –⁠ genetic predictors. Biomedical Papers 2013; 157 (2): 125–136. doi: 10.5507/bp.2013.034.

67. Jančík S, Drábek J, Radzioch D et al. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010 : 150960. doi: 10.1155/2010/150960.

68. Saha E, Ben Guebila M, Fanfani V et al. Gene regulatory networks reveal sex difference in lung adenocarcinoma. Biol Sex Differ 2024; 15 (1): 62. doi: 10.1186/s13293-024-00634-y.

69. Siegfried JM. Sex and gender differences in lung cancer and chronic obstructive lung disease. Endocrinology 2022; 163 (2): bqab254. doi: 10.1210/endocr/bqab254.

70. May L, Shows K, Nana-Sinkam P et al. Sex differences in lung cancer. Cancers (Basel) 2023; 15 (12): 3111. doi: 10.3390/cancers15123111.

71. Vavalà T, Catino A, Pizzutilo P et al. Gender differences and immunotherapy outcome in advanced lung cancer. Int J Mol Sci 2021; 22 (21): 11942. doi: 10.3390/ijms222111942.

72. Payne S. “Smoke like a man, die like a man”?: a review of the relationship between gender, sex and lung cancer. Soc Sci Med 2001; 53 (8): 1067–1080. doi: 10.1016/s0277-9536 (00) 00402-0.

73. de Jong JJ, Boormans JL, van Rhijn BWG et al. Distribution of molecular subtypes in muscle-invasive bladder cancer is driven by sex-specific differences. Eur Urol Oncol 2020; 3 (4): 420–423. doi: 10.1016/j.euo.2020.02.010.

74. Chaudhary P, Singha B, Abdel-Hafiz HA et al. Sex differences in bladder cancer: understanding biological and clinical implications. Biol Sex Differ 2025; 16 (1): 31. doi: 10.1186/s13293-025-00715-6.

75. Doshi B, Athans SR, Woloszynska A. Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions. Oncogenesis 2023; 12 (1): 44. doi: 10.1038/s41389-023-00489-9.

76. Toren P, Wilkins A, Patel K et al. The sex gap in bladder cancer survival –⁠ a missing link in bladder cancer care? Nat Rev Urol 2024; 21 (3): 181–192. doi: 10.1038/s41585-023-00806-2.

77. Koutros S, Kiemeney LA, Pal Choudhury P et al. Genome-wide association study of bladder cancer reveals new biological and translational insights. Eur Urol 2023; 84 (1): 127–137. doi: 10.1016/j.eururo.2023.04.020.

78. Barone B, Finati M, Cinelli F et al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. J Pers Med 2023; 13 (3): 512. doi: 10.3390/jpm1 3030512.

79. Papavasileiou G, Tsilingiris D, Spyrou N et al. Obesity and main urologic cancers: current systematic evidence, novel biological mechanisms, perspectives and challenges. Semin Cancer Biol 2023; 91 : 70–98. doi: 10.1016/j.semcancer.2023.03.002.

80. Deltourbe LG, Durand M, Costas A et al. A bladder blueprint to build better models for understanding homeostasis and disease. Nat Rev Urol 2025; 22 (8): 496–508. doi: 10.1038/s41585-025-01013-x.

81. Kalff MC, Wagner AD, Verhoeven RHA et al. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer 2022; 25 (1): 22–32. doi: 10.1007/s10120-021-01225-1.

82. Park JO, Nam IC, Kim CS et al. Sex differences in the prevalence of head and neck cancers: a 10-year follow-up study of 10 million healthy people. Cancers (Basel) 2022; 14 (10): 2521. doi: 10.3390/cancers14102521.

83. Quaas A, Biesma HD, Wagner AD et al. Microsatellite instability and sex differences in resectable gastric cancer –⁠ a pooled analysis of three European cohorts. Eur J Cancer 2022; 173 : 95–104. doi: 10.1016/j.ejca.2022.06.025.

84. Clausen F, Behrens HM, Krüger S et al. Sexual dimorphism in gastric cancer: tumor-associated neutrophils predict patient outcome only for women. J Cancer Res Clin Oncol 2020; 146 (1): 53–66. doi: 10.1007/s00432-019-03082-z.

85. Li WZ, Lv SH, Liu GY et al. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biol Sex Differ 2021; 12 (1): 18. doi: 10.1186/s13293-021-00361-8.

86. Oertelt-Prigione S, de Rooij BH, Mols F et al. Sex-differences in symptoms and functioning in >5000 cancer survivors: results from the PROFILES registry. Eur J Cancer 2021; 156 : 24–34. doi: 10.1016/j.ejca.2021.07.019.

87. Benderli Cihan Y, Ozturk O. The effect of demographic and clinical data on anxiety and depression levels in breast cancer patients receiving radiotherapy. Klin Onkol 2023; 36 (6): 453–461. doi: 10.48095/ccko2023453.

88. Wang Y, Jiao Y, Nie J et al. Sex differences in the association between marital status and the risk of cardiovascular, cancer, and all-cause mortality: a systematic review and meta-analysis of 7,881,040 individuals. Glob Health Res Policy 2020; 5 (1): 4. doi: 10.1186/s41256-020 -⁠ 00133-8.

89. Glantz MJ, Chamberlain MC, Liu Q et al. Gender disparity in the rate of partner abandonment in patients with serious medical illness. Cancer 2009; 115 (22): 5237–5242. doi: 10.1002/cncr.24577.

90. Karraker A, Latham K. In sickness and in health? Physical illness as a risk factor for marital dissolution in later life. J Health Soc Behav 2015; 56 (3): 420–435. doi: 10.1177/0022146515596354.

91. Stephens C, Westmaas JL, Kim J et al. Gender differences in associations between cancer-related problems and relationship dissolution among cancer survivors. J Cancer Surviv 2016; 10 (5): 865–873. doi: 10.1007/s11764-016-0532-9.

92. Rodrigues-Machado N, Bonfill-Cosp X, Quintana MJ et al. Sexual dysfunction in women with breast cancer: a systematic review. Support Care Cancer 2025; 33 (4): 332. doi: 10.1007/s00520-025-09352-6.

93. Markopoulos C, Tsaroucha A, Kouskos E et al. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. J Int Med Res 2009; 37 (1): 182–188. doi: 10.1177/147323000903700122.

94. Albaugh JA, Sufrin N, Lapin BR et al. Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners. BMC Urol 2017; 17 (1): 45. doi: 10.1186/s12894-017-0231-5.

95. Chambers SK, Chung E, Wittert G et al. Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment. Transl Androl Urol 2017; 6 (1): 60–68. doi: 10.21037/tau.2016.08.12.

96. Kinnaird W, Schartau P, Kirby M et al. Sexual dysfunction in prostate cancer patients according to disease stage and treatment modality. Clin Oncol 2025; 41 : 103801. doi: 10.1016/j.clon.2025.103801.

97. Heyne S, Taubenheim S, Dietz A et al. Physical and psychosocial factors associated with sexual satisfaction in long-term cancer survivors 5 and 10 years after diagnosis. Sci Rep 2023; 13 (1): 2011. doi: 10.1038/s41598-023-28496-1.

98. Umberson D, Thomeer MB, Reczek C et al. Physical illness in gay, lesbian, and heterosexual marriages. J Health Soc Behav 2016; 57 (4): 517–531. doi: 10.1177/0022146516671570.

99. Pratt-Chapman ML, Alpert AB, Castillo DA. Health outcomes of sexual and gender minorities after cancer: a systematic review. Syst Rev 2021; 10 (1): 183. doi: 10.1186/s13643-021-01707-4.

100. Barešová Z, Světlák M, Vigašová D et al. EHealth support for mental health of oncology patients –⁠ is there patient interest? Summary of the first year with the MOÚ MindCare mobile application. Klin Onkol 2023; 36 (Suppl 1): 119–122. doi: 10.48095/ccko202 3S119.

101. Jang B, Yoon D, Lee JY et al. Integrative multi-omics characterization reveals sex differences in glioblastoma. Biol Sex Differ 2024; 15 (1): 23. doi: 10.1186/s13293-024-00601-7.

102. Costanzo M, Caterino M, Sotgiu G et al. Sex differences in the human metabolome. Biol Sex Differ 2022; 13 (1): 30. doi: 10.1186/s13293-022-00440-4.

103. de Visser C, Niehues A, Najdekr L, et al. Comprehensive multi-omics profiling of a healthy human cohort. 2024 [online]. Dostupné z: https: //www.biorxiv.org/content/10.1101/2024.11.07.622407v1.full.

104. Surinova S, Choi M, Tao S et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med 2015; 7 (9): 1166–1178. doi: 10.15252/emmm.201404873.

105. Lopes-Ramos CM, Chen CY, Kuijjer ML et al. Sex differences in gene expression and regulatory networks across 29 human tissues. Cell Rep 2020; 31 (12): 107795. doi: 10.1016/j.celrep.2020.107795.

106. Li CH, Prokopec SD, Sun RX et al. Sex differences in oncogenic mutational processes. Nat Commun 2020; 11 (1): 4330. doi: 10.1038/s41467-020-17359-2.

107. Docherty JR, Stanford SC, Panettieri RA et al. Sex: a change in our guidelines to authors to ensure that this is no longer an ignored experimental variable. Br J Pharmacol 2019; 176 (21): 4081–4086. doi: 10.1111/bph.14761.

108. Kourou K, Exarchos TP, Exarchos KP et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J 2015; 13 : 8–17. doi: 10.1016/j.csbj.2014.11.005.

109. Özdemir BC, Dotto GP. Sex hormones and anticancer immunity. Clin Cancer Res 2019; 25 (15): 4603–4610. doi: 10.1158/1078-0432.CCR-19-0137.

110. Xiao T, Lee J, Gauntner TD et al. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer 2024; 24 (5): 338–355. doi: 10.1038/s41568-024-00680-z.

111. Gemmati D, Varani K, Bramanti B et al. “Bridging the gap” everything that could have been avoided if we had applied gender medicine, pharmacogenetics and personalized medicine in the gender-omics and sex-omics era. Int J Mol Sci 2019; 21 (1): 296. doi: 10.3390/ijms21010296.

112. ÚZIS. Registry a sběr dat. [onine]. Dostupné z. https: //www.uzis.cz/index.php?pg=registry-sber-dat.